Alembic Pharmaceuticals received USFDA approval for its Sumatriptan injection, a generic equivalent for treating migraines and cluster headaches. This marks Alembic's first drug device combination.

Ltd on Monday said it has received final approval from the US health regulator for its generic version of Sumatriptan injection used in treatment of migraine.   The approval by the US Food & Drug ...

FDA issued 18 warning letters to websites selling unapproved or misbranded botulinum toxin products. Officials say the ...

It began as an odd observation among plastic surgery patients, and ended up as an FDA approved drug — on Friday, the agency green-lighted the use of Botox, a popular wrinkle-reducing procedure, to ...

Brekiya®, a ready-to-use dihydroergotamine (DHE) autoinjector, is now available for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...

Migraines are more than an occasional nuisance for some. Those suffering from chronic migraines know all too well the nausea, sensitivity, and unbearable pain that comes along with frequent attacks.

Learn all about chronic migraine: its diagnosis, symptoms, risk factors, and effective treatments. Discover lifestyle ...

The University of Miami Miller School of Medicine is offering a new treatment for migraines involving IV injections administered to a patient over several days, according to a Miami Herald report. The ...

(Reuters) - Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers. Bracing for a flood of costly prescription ...

NEW YORK Results from two clinical studies presented at this year’s American Headache Society meeting could help a needle-free migraine drug from Zogenix get Food and Drug Administration approval. The ...